Small Molecule Inhibitors Induce Conformational Changes in the I Domain and the I-like Domain of Lymphocyte Function-associated Antigen-1
Open accessThe DOI matches its Crossref record.
Abstract
The beta(2) integrin lymphocyte function-associated antigen-1 (LFA-1) is a conformationally flexible alpha/beta heterodimeric receptor, which is expressed on the surface of all leukocytes. LFA-1 mediates cell adhesion crucial for normal immune and inflammatory responses. Intracellular signals or cations are required to convert LFA-1 from a nonligand binding to a ligand binding state. Here we investigated the effect of small molecule inhibitors on LFA-1 by monitoring the binding of monoclonal antibodies mapped to different receptor domains. The inhibitors were found to not only induce epitope changes in the I domain of the alpha(L) chain but also in the I-like domain of the beta(2) chain depending on the individual chemical structure of the inhibitor and its binding site. For the first time, we provide strong evidence that the I-like domain represents a target for allosteric LFA-1 inhibition similar to the well established regulatory L-site on the I domain of LFA-1. Moreover, the antibody binding patterns observed in the presence of the various inhibitors establish a conformational interaction between the LFA-1 I domain and the I-like domain in the native receptor that is formed upon activation. Differentially targeting the binding sites of the inhibitors, the L-site and the I-like domain, may open new avenues for highly specific therapeutic intervention in diseases where integrins play a pathophysiological role.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705
“The other class of allosteric inhibitors seems to bind at the junction between the I-domain and the I-like domain, blocking the interaction of the α7 helix with the I-like domai”
BackgroundStructural Basis of Integrin Regulation and Signaling
Luo, B.-H., Carman, C. V., & Springer, T. A. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141618 · Cited by 1,660
INTEGRIN STRUCTURE, ALLOSTERY, AND BIDIRECTIONAL SIGNALING
Arnaout, M. A., Mahalingam, B., & Xiong, J.-P. (2005) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.21.090704.151217 · Cited by 550
Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer
Gazzerro, P., Proto, M. C., Gangemi, G., Malfitano, A. M., Ciaglia, E., Pisanti, S., Santoro, A., Laezza, C., & Bifulco, M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004994 · Cited by 457
Integrins as therapeutic targets: lessons and opportunities
Cox, D., Brennan, M., & Moran, N. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3266 · Cited by 456
Strategies for Targeting Protein–Protein Interactions With Synthetic Agents
Yin, H., & Hamilton, A. D. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200461786 · Cited by 453
Integrin activation and structural rearrangement
Takagi, J., & Springer, T. A. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18613.x · Cited by 384
Therapeutic antagonists and conformational regulation of integrin function
Shimaoka, M., & Springer, T. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1174 · Cited by 349
Modulation of Protein–Protein Interactions with Small Organic Molecules
Berg, T. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200200558 · Cited by 292
Activation of Leukocyte β2 Integrins by Conversion from Bent to Extended Conformations
Nishida, N., Xie, C., Shimaoka, M., Cheng, Y., Walz, T., & Springer, T. A. (2006) · Immunity · doi:10.1016/j.immuni.2006.07.016 · Cited by 262
Chen, W., Lou, J., & Zhu, C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.155770 · Cited by 183
Ni, D., Lu, S., & Zhang, J. (2019) · Medicinal Research Reviews · doi:10.1002/med.21585 · Cited by 116
“Most allosteric modulators targeted to this site originate from drug companies such as Genentech and Roche.(154,155) These modulators were initially designed to mimic the epitope and the effect of ICAM‐1; therefore, amino acid functionalities involved in the LFA‐1‐ICAM‐1 PPI were grafted for optimization and led to th…”
BackgroundProtein-Protein Interactions as Drug Targets
Wendt, M. D. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_1 · Cited by 9
Metadata
- Authors
- Welzenbach, K., Hommel, U., & Weitz-Schmidt, G.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2002-03
- Volume
- 277
- Issue
- 12
- Pages
- 10590-10598
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1988373084
- Cited by
- 81
- References
- 0
- FWCI
- 4.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.